Late clonal diseases of treated aplastic anemia.
Recent progress in the treatment of aplastic anemia has dramatically changed the previously grim prognosis for these patients. Improvements in bone marrow transplantation and immunosuppression have increased the number of long-term survivors so that immediate survival is no longer the sole concern. Here, we review the major clinical studies and summarize recent analyses of risk factors for developing paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute leukemia, or solid tumor after treatment for aplastic anemia. We also examine biologic clues that may shed light on the interrelationship between aplastic anemia and clonal diseases.
Socié
G
G
Service d'Hématologie Greffe de Moelle Hôpital Saint Louis, Paris, France.
Rosenfeld
S
S
Frickhofen
N
N
Gluckman
E
E
Tichelli
A
A
D000741:Anemia, Aplastic / Q000150:complications* / Q000628:therapy*; D016026:Bone Marrow Transplantation; D006457:Hemoglobinuria, Paroxysmal / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents; D007938:Leukemia / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000209:etiology; D009369:Neoplasms / Q000209:etiology; D012307:Risk Factors
D007166:Immunosuppressive Agents